![kisqali side effect kisqali side effect](https://www.magicinepharma.com/img/products/banners/39c5b7174ed61f11689f04712fe31fc6.jpg)
Kisqali side effect trial#
“These remarkable ribociclib overall survival data are highly encouraging and represent the longest reported median survival from a randomized trial in HR+/HER2- advanced breast cancer. MONALEESA-2 showed that after five years, patients treated with Kisqali in combination with letrozole had more than a 50% chance of survival (52.3% vs. The analysis found that after a median follow-up of over six and a half years, the longest for any CDK4/6 inhibitor trial to date, the improvement in the median OS was over one year 2. Kisqali in combination with letrozole met its key secondary endpoint of OS, demonstrating a statistically significant and clinically meaningful improvement in survival (median 63.9 vs.
![kisqali side effect kisqali side effect](https://www.us.kisqali.com/globalassets/migration-root/products.com/kisqali-wip/products/kisqali---full-promo/images/images/moa_image_1024_5101_resized.jpg)
These data will be presented as a late-breaker oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021 on September 19 (#LBA17).
Kisqali side effect plus#
The digital press release with multimedia content can be accessed here:īasel, SeptemNovartis today announced results of the final overall survival (OS) analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali ® (ribociclib) in combination with letrozole compared to placebo plus letrozole in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer with no prior systemic treatment for advanced disease.